What are the recommended first-line treatments for a patient diagnosed with Chronic Myeloid Leukaemia (CML)?

For patients diagnosed with chronic myeloid leukaemia (CML) in the chronic phase, the recommended first-line treatments primarily involve tyrosine kinase inhibitors (TKIs) ¹. These agents are considered the standard of care for initial therapy (García-Gutiérrez et al., 2022). Specific TKIs commonly used as first-line options include imatinib, nilotinib, dasatinib, and bosutinib (García-Gutiérrez et al., 2022). The choice among these TKIs may depend on various factors, including patient characteristics and physician preference (Deininger et al., 2020; García-Gutiérrez et al., 2022). For children and adolescents with CML in the chronic phase, TKI therapy is also the recommended approach (Millot et al., 2025).